Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer - ESMO Open
Diagnosis and Discussion -- Case 1068
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Diagnosis and Discussion -- Case 1068
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Analysis of MET kinase domain rearrangement in NSCLC - Lung Cancer
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
EGFR pathway in NSCLC. Mutations, amplification or overexpression of... | Download Scientific Diagram
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations - Journal of Thoracic Oncology
Mutational profiles in non-small cell lung cancer. (A) Oncogenic driver... | Download Scientific Diagram
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
MEK inhibitors against MET-amplified non-small cell lung cancer
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Lung cancer with MET exon 14 skipping mutation | LCTT
![PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/df73d74a72129de1592255fc0a74db3d4b45eef3/2-Figure1-1.png "PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar")